VANI
Skin in the game
Vivani Medical director Williams Gregg stepped in and bought 1,587,301 shares of common stock for roughly $1.99 million on April 15, paying $1.26 a share.
That’s not a tiny “I believe in the team” nibble. That’s a pretty chunky vote of confidence, and the market tends to notice when a director goes shopping with real money instead of just a motivational LinkedIn post.
Why investors care
Insider buys can matter because they often signal that someone close to the business thinks the shares are undervalued or that better days are ahead. In this case, the stock is already trading at $1.14, below the purchase price, which makes the buy look even a little more conviction-heavy.
The big picture
- Vivani shares were up 9.62% over the past week, so the stock already had some momentum.
- A director buying this size doesn’t guarantee anything, but it can act like a tiny flashlight in a foggy biotech story.
- If you’re watching VANI, this is one of those “management put some chips on the table” moments.
Big picture: insider buys aren’t magic, but they’re usually not random. When a director opens their wallet this wide, it’s worth paying attention.